What do systematic reviews say?

Honey vs standard dressing

• Honey as a topical treatment for wounds 2015 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 213 participants
  Very low

Honey vs standard dressing

It is very uncertain whether honey changes adverse events compared with conventional dressings (very low certainty).

• Honey as a topical treatment for wounds 2015 · Cochrane Headline outcomes only
  RR 1.19 [0.69, 2.05]
  1 study · 82 participants
  Very low

Honey vs standard dressing

It is very uncertain whether honey changes infection compared with conventional dressings (very low certainty).

• Honey as a topical treatment for wounds 2015 · Cochrane Headline outcomes only
  RR 0.91 [0.13, 6.37]
  3 studies · 151 participants
  Very low

Honey vs standard dressing

• Honey as a topical treatment for wounds 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 82 participants
  Very low

Honey vs standard dressing

The review found no eligible studies for this question.

• Honey as a topical treatment for wounds 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Misoprostol vs dinoprostone before operative hysteroscopy

• Preoperative ripening of the cervix before operative hysteroscopy 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Misoprostol vs dinoprostone before operative hysteroscopy

Misoprostol may leads to lower ease of dilatation: need for mechanical dilatation compared with dinoprostone before operative hysteroscopy (low certainty).

• Preoperative ripening of the cervix before operative hysteroscopy 2015 · Cochrane Headline outcomes only
  OR 0.58 [0.34, 0.98]
  1 study · 310 participants
  Low

Misoprostol vs dinoprostone before operative hysteroscopy

Misoprostol may leads to lower intraoperative complications compared with dinoprostone before operative hysteroscopy (low certainty).

• Preoperative ripening of the cervix before operative hysteroscopy 2015 · Cochrane Headline outcomes only
  OR 0.32 [0.12, 0.83]
  1 study · 310 participants
  Low

Index pricing vs no index pricing

The review found no eligible studies for this question.

• Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Index pricing vs no index pricing

The review found no eligible studies for this question.

• Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Index pricing vs no index pricing

The review found no eligible studies for this question.

• Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Index pricing vs no index pricing

The review found no eligible studies for this question.

• Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Index pricing vs no index pricing

• Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Index pricing vs no index pricing

• Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Index pricing vs no index pricing

The review found no eligible studies for this question.

• Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Methotrexate vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

It is very uncertain whether methotrexate changes proportion of patients achieved clinical remission compared with 5‐aminosalicylic acid (5‐ASA) (very low certainty).

• Methotrexate for induction of remission in ulcerative colitis 2014 · Cochrane Headline outcomes only
  RR 2.33 [0.66, 3.64]
  1 study · 20 participants
  Very low

Tetracycline vs quinolones

• Antimicrobial drugs for treating cholera 2014 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 259 participants
  Moderate

Tetracycline vs quinolones

• Antimicrobial drugs for treating cholera 2014 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 236 participants
  Low

Tetracycline vs quinolones

Tetracycline showed no clear difference in bacteriological failure compared with quinolones (low certainty).

• Antimicrobial drugs for treating cholera 2014 · Cochrane Headline outcomes only
  RR 0.99 [0.14, 6.82]
  2 studies · 234 participants
  Low

Doxycycline vs quinolones

• Antimicrobial drugs for treating cholera 2014 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 126 participants
  Low